STOCK TITAN

Cellectis - CLLS STOCK NEWS

Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.

About Cellectis

Cellectis (NASDAQ: CLLS) is a clinical-stage biopharmaceutical company at the forefront of gene-editing technologies, dedicated to developing innovative cancer immunotherapies and other therapeutic solutions. Leveraging over 18 years of expertise in genome engineering, Cellectis has established itself as a pioneer in the field, utilizing its proprietary TALEN® (Transcription Activator-Like Effector Nucleases) technology and PulseAgile electroporation system to create precise, next-generation therapies. These tools enable the company to harness the immune system's power to target and eliminate cancer cells effectively.

Core Focus: Allogeneic CAR-T and Gene-Edited HSPCs

Cellectis specializes in developing allogeneic Chimeric Antigen Receptor T-cells (UCART) for immuno-oncology applications. Unlike traditional autologous CAR-T therapies, which require harvesting and engineering a patient’s own cells, Cellectis’s allogeneic approach uses gene-edited donor cells. This innovation offers scalability, reduced manufacturing costs, and faster availability, making it a game-changer in cancer treatment. Additionally, the company is advancing gene-edited hematopoietic stem and progenitor cells (HSPCs) for therapeutic indications beyond oncology, showcasing its versatility in genome editing.

Proprietary Technologies

Cellectis’s competitive edge lies in its proprietary technologies:

  • TALEN® Technology: A precise and versatile gene-editing tool that enables targeted modifications to DNA, ensuring high specificity and minimal off-target effects.
  • PulseAgile Electroporation System: A cutting-edge delivery platform that enhances the efficiency of introducing genetic material into cells.

These technologies form the backbone of Cellectis’s product pipeline, enabling the development of innovative therapies that address unmet medical needs.

Market Position and Industry Context

Cellectis operates within the rapidly growing fields of immuno-oncology and precision medicine. The global demand for effective cancer therapies continues to rise, driven by advancements in biotechnology and an increasing understanding of the immune system's role in combating diseases. As a clinical-stage company, Cellectis focuses on research and development, with a pipeline of promising product candidates undergoing rigorous clinical trials. However, this stage also presents challenges, including regulatory approvals, high R&D costs, and competition from other biotech firms specializing in gene editing and CAR-T therapies.

Competitive Landscape

Key competitors in the gene-editing and CAR-T therapy space include CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics. Cellectis differentiates itself through its allogeneic approach, which offers significant advantages in scalability and cost-effectiveness. By addressing the limitations of autologous therapies, such as manufacturing complexity and patient-specific variability, Cellectis positions itself as a leader in next-generation cancer immunotherapies.

Challenges and Opportunities

While Cellectis’s innovative approach holds immense promise, the company faces several challenges. These include navigating a complex regulatory environment, managing high development costs, and competing in a crowded market. However, the potential rewards are substantial, with successful therapies offering transformative benefits for patients and significant market opportunities. The company’s focus on leveraging proprietary technologies and addressing unmet medical needs positions it well for long-term success.

Conclusion

Cellectis is a trailblazer in the biopharmaceutical industry, combining cutting-edge gene-editing technologies with a commitment to innovation in cancer immunotherapy and beyond. By leveraging its proprietary TALEN® technology and allogeneic approach, the company aims to revolutionize the treatment landscape, offering scalable, cost-effective solutions to some of the most pressing medical challenges. As a clinical-stage entity, Cellectis represents a high-risk, high-reward opportunity within the dynamic biotechnology sector.

Rhea-AI Summary
Cellectis announces voting rights for February 2024 with a total of 77,686,895 voting rights and 71,751,201 shares in the capital. The company's ISIN code is FR0010425595, listed on Euronext Growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.62%
Tags
none
-
Rhea-AI Summary
Cellectis (CLLS) reports a total number of shares in the capital and voting rights as of January 31, 2024. The company's ISIN code is FR0010425595 and is listed on Euronext Growth. Media and investor relations contacts are provided for further information.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
none
-
Rhea-AI Summary
Cellectis, a clinical-stage biotechnology company, has announced the drawdown of the second tranche of €15 million under a credit facility agreement with the European Investment Bank. The company plans to use the proceeds towards the development of its pipeline of allogeneic CAR T-cell product candidates. As a condition to the disbursement, the company issued warrants to the EIB, allowing them to subscribe for one ordinary share of the company at a specific price. The total number of shares issuable upon exercise of the warrants represents circa 2% of the company’s outstanding share capital at their issuance date. The tranche will mature in six years and accrue interest at a rate of 7% per annum. The company also has the option to drawdown a third tranche of up to €5 million, subject to certain conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.42%
Tags
none
Rhea-AI Summary
Cellectis (Euronext Growth: FR0010425595) reports a total number of shares in the capital as 71,751,201 and a total number of voting rights as 77,686,718 as of December 31, 2023. For further information, media contact is Patricia Sosa Navarro at +33 (0)7 76 77 46 93, media@cellectis.com. Investor Relations contacts are Arthur Stril at +1 (347) 809 5980, investors@cellectis.com and Ashley R. Robinson at +1 617 430 7577.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
none
-
Rhea-AI Summary
Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS) held a shareholders general meeting at which resolutions 1 through 5 and 7 and 8 were adopted and resolution 6 was rejected. Shareholders supported a contemplated $140M additional investment by AstraZeneca, subject to clearance from the French Ministry of Economy. Mr. Marc Dunoyer and Dr. Tyrell Rivers were approved as directors of the Cellectis board of directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Cellectis (Euronext Growth: ALCLS) reports a total number of 71,751,201 shares in the capital and 77,686,109 voting rights as of November 30, 2023. For further information, please contact Media Chief of Staff Patricia Sosa Navarro at +33 (0)7 76 77 46 93 or media@cellectis.com, and Investor Relations Chief Business Officer Arthur Stril at +1 (347) 809 5980 or investors@cellectis.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.59%
Tags
none
Rhea-AI Summary
Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS) to hold a general meeting on December 22, 2023, at 2:30 p.m. CET at the Biopark auditorium in Paris, France. The notice of meeting, agenda, resolutions, and terms of participation are available on the Cellectis website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.8%
Tags
none
-
Rhea-AI Summary
Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) has signed a binding Subsequent Investment Agreement with AstraZeneca regarding the additional equity investment of $140M previously announced. AstraZeneca will subscribe to 10,000,000 'class A' convertible preferred shares and 18,000,000 'class B' convertible preferred shares at $5.00 per share. The approval of an extraordinary shareholders’ meeting of Cellectis and clearance from the French Ministry of Economy are required before the closing of the investment, which is expected to result in AstraZeneca owning approximately 44% of the share capital and 30% of the voting rights of Cellectis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.37%
Tags
none
-
Rhea-AI Summary
Cellectis, a clinical-stage biotechnology company, has signed strategic collaboration and investment agreements with AstraZeneca. The collaboration will leverage Cellectis' gene editing technologies to develop next-generation therapeutics in areas of high unmet need. Cellectis' clinical-stage assets will remain under its ownership. The company also provided updates on its clinical trials and preclinical programs, including the BALLI-01 trial evaluating UCART22 and the NATHALI-01 trial evaluating UCART20x22. Cellectis has a cash position of $721 million as of September 30, 2023, providing a cash runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.41%
Tags
Rhea-AI Summary
Cellectis, a company listed on Euronext Growth, has a total of 55,583,768 shares in its capital and 61,519,396 voting rights as of October 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.5%
Tags
none

FAQ

What is the current stock price of Cellectis (CLLS)?

The current stock price of Cellectis (CLLS) is $1.32 as of April 1, 2025.

What is the market cap of Cellectis (CLLS)?

The market cap of Cellectis (CLLS) is approximately 131.1M.

What does Cellectis specialize in?

Cellectis specializes in developing gene-edited cancer immunotherapies, particularly allogeneic CAR-T cells, and other therapeutic applications using its proprietary TALEN® technology.

How does Cellectis differentiate from competitors?

Cellectis focuses on allogeneic CAR-T therapies, which offer scalability and cost advantages over autologous approaches. Its proprietary TALEN® technology ensures precise gene editing.

What are Cellectis’s proprietary technologies?

Cellectis utilizes TALEN® for precise gene editing and the PulseAgile electroporation system for efficient genetic material delivery into cells.

What challenges does Cellectis face?

As a clinical-stage company, Cellectis faces challenges such as regulatory hurdles, high R&D costs, and competition from other biotech firms in the gene-editing and immunotherapy space.

What is the significance of allogeneic CAR-T therapies?

Allogeneic CAR-T therapies use gene-edited donor cells, providing scalability, reduced manufacturing costs, and faster availability compared to patient-specific autologous therapies.

What market does Cellectis target?

Cellectis targets the immuno-oncology market with its cancer immunotherapies and explores other therapeutic indications through gene-edited hematopoietic stem and progenitor cells.

Who are Cellectis’s main competitors?

Competitors include CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics, all of which focus on gene-editing technologies and related therapies.

What stage of development is Cellectis in?

Cellectis is a clinical-stage biopharmaceutical company, focusing on research, development, and clinical trials for its product candidates.
Cellectis

Nasdaq:CLLS

CLLS Rankings

CLLS Stock Data

131.12M
69.31M
3.87%
20.71%
0.24%
Biotechnology
Healthcare
Link
France
Paris